Loading clinical trials...
Loading clinical trials...
Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn
Conditions
Interventions
Placebo
Ad4-H5-Vtn
+1 more
Locations
4
United States
University of Kentucky
Lexington, Kentucky, United States
The Center for Pharmaceutical Research
Kansas City, Missouri, United States
University of Rochester
Rochester, New York, United States
Coastal Carolina Research Center, Inc.
Mt. Pleasant, South Carolina, United States
Start Date
October 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
March 18, 2024
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Emergent BioSolutions
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions